CNMD CONMED Corp
FY2025 10-K
CONMED Corp (CNMD) filed its fiscal year 2025 10-K annual report with the SEC on Feb 17, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model centered on medical industry products and services, emphasizing talent attraction and retention amid intense competition
- • Suspension of quarterly dividend payments since October 2025 to extend share repurchase program, with future dividends uncertain due to financial and legal constraints
Management Discussion & Analysis
- • Revenue $555M, flat YoY with orthopedic surgery and general surgery stable at 42% and 58% of sales respectively
- • Gross margin 48.3% vs 49.1% in prior year, reflecting inflationary cost pressures and supply chain challenges
Risk Factors
- • Financial risk $840M long-term debt with $800M convertible notes due 2027 requiring incremental financing
- • Operational risk increased capital spending expected in 2026 funded by operating cash flow with monitored control
Get deeper insights on CONMED Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.